<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00859014</url>
  </required_header>
  <id_info>
    <org_study_id>N01-HB-37163-05</org_study_id>
    <secondary_id>R21HD060978</secondary_id>
    <nct_id>NCT00859014</nct_id>
  </id_info>
  <brief_title>Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients</brief_title>
  <official_title>Safety/Feasibility of Autologous Mononuclear Bone Marrow Cells in Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out if bone marrow treatment (bone marrow
      aspiration and infusion of stem cells) can be safely used in adults who have recently (within
      24-72 hours)suffered an acute ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our primary hypothesis is that autologous bone marrow mononuclear cell transplantation by
      intravenous administration is feasible and safe after acute ischemic stroke. Our secondary
      hypothesis is that autologous transplantation is associated with improved outcome after acute
      stroke.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Study Related Serious Adverse Events (SR-SAE)</measure>
    <time_frame>2 Years</time_frame>
    <description>Study Related Serious Adverse Events (SAE) as adjudicated by the DSMB - &quot;Events&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Outcome</measure>
    <time_frame>90-days</time_frame>
    <description>Modified Rankin Scale (mRS) Score. The mRS is a six point (scored: 0 - 5) scale that measures post stroke disability. A seventh category (mRS = 6) is for patients who have died. A higher score indicates greater degree of disability. Patients scoring '5' are bed ridden, where as those scoring '0' are completely symptom free and independent.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Autologous Bone Marrow Mononuclear Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Bone Marrow Mononuclear Cells</intervention_name>
    <description>Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells</description>
    <arm_group_label>Autologous Bone Marrow Mononuclear Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. acute ischemic stroke

          2. age 18 to 83 years If &gt;80 then the pre-stroke mRS needs to be &lt; 1)

          3. Right hemisphere NIHSS 6 -15, left hemisphere NIHSS 6-18

          4. known onset time of acute symptoms

          5. stem cell transplantation procedure must be performed within 24 to 72 hrs after stroke
             symptom onset

          6. TPA infusion is allowed

        Exclusion Criteria:

          1. NIHSS 1a &gt; 1

          2. pre-stroke mRS &gt; 1 if &gt; 80 years of age

          3. Ischemic stroke in the last 3 months, any vascular territory

          4. MI, primary hemorrhagic or traumatic lesion of the brain within the last 3 months or
             identified on MRI. Small hemorrhagic transformation of the acute infarct is allowed.

          5. seizure disorder

          6. developmental delay

          7. chronic kidney disease defined as baseline creatinine &gt;1.4

          8. hepatic disease or altered liver function as defined by SGPT &gt;150 U/L and or T.
             Bilirubin &gt;1.6 mg/dL at admission

          9. pulmonary disease (e.g, COPD with oxygen-requirement at rest or with ambulation,
             moderate to severe asthma)

         10. mechanical heart valve

         11. Active malignancy or diagnosis of malignancy within 5 years prior to the start of
             screening or any history of chemotherapy or radiation affecting the bone marrow. Skin
             cancers (except for melanoma) are permitted.

         12. prior immunosuppression, including chemotherapy administration within last 3 years or
             current immunosuppression as defined by WBC &lt;3 x 103 cells/ml

         13. known HIV

         14. hemoglobin &lt;10g/dl

         15. uncorrected coagulopathy at the time of consent defined as INR &gt;1.4; PTT&gt;37 sec, or
             thrombocytopenia (PLT&lt;100,000)

         16. any hemodynamic instability at the time of consent (e.g, requiring continuous fluid
             resuscitation or ionotropic support).

         17. Hypoxemia (SaO2&lt;90%) at the time of consent, respiratory distress or persistent
             hypoxemia defined as SaO2 &lt;94% for &gt;30 minutes occurring at any time from hospital
             admission to time of consent. Intubation alone is not an exclusion.

         18. pregnancy or positive b-HCG

         19. current participation in any interventional research study

         20. unable to return for follow-up visits for clinical evaluation, laboratory studies, or
             imaging evaluation

         21. Multiple anti-platelet medications (Aggrenox is considered a single platelet agent)

         22. Unable to undergo MRI or CT scan

         23. Any other condition that the investigator feels would pose a significant hazard to the
             patient if enrolled.

         24. Exclude infarct lesion size &gt;145cc unless the NIHSS 1a remains &lt; 1 and there is no
             evidence of infarct expansion or edema formation on any imaging obtained from
             admission up to the point just prior to infusion.

         25. Exclude IA therapy use or if there is a planned or anticipated hemicraniectomy.
             Diagnostic angiograms are allowed

         26. CT and/or Multimodal MRI exclusion criteria will be:

               -  hemispheric strokes &lt; 1.5 cm maximum diameter (on the MRI as seen on the
                  diffusion-weighted imaging or CT)

               -  midline shift &gt;1mm or significant hemorrhagic transformation of the acute infarct
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>83 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean I Savitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Heath Science Center- Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital-Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Vahidy FS, Alderman S, Savitz SI. Challenges enrolling patients with acute ischemic stroke into cell therapy trials. Stem Cells Dev. 2013 Jan 1;22(1):27-30. doi: 10.1089/scd.2012.0404. Epub 2012 Oct 15.</citation>
    <PMID>22970907</PMID>
  </reference>
  <results_reference>
    <citation>Savitz SI, Misra V, Kasam M, Juneja H, Cox CS Jr, Alderman S, Aisiku I, Kar S, Gee A, Grotta JC. Intravenous autologous bone marrow mononuclear cells for ischemic stroke. Ann Neurol. 2011 Jul;70(1):59-69. doi: 10.1002/ana.22458.</citation>
    <PMID>21786299</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>December 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 1, 2015</results_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Sean Savitz</investigator_full_name>
    <investigator_title>Professor, Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Autologous Bone Marrow Mononuclear Cells</title>
          <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Total number of study participants</population>
      <group_list>
        <group group_id="B1">
          <title>Autologous Bone Marrow Mononuclear Cells</title>
          <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Study Related Serious Adverse Events (SR-SAE)</title>
        <description>Study Related Serious Adverse Events (SAE) as adjudicated by the DSMB - &quot;Events&quot;</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Bone Marrow Mononuclear Cells</title>
            <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Related Serious Adverse Events (SR-SAE)</title>
          <description>Study Related Serious Adverse Events (SAE) as adjudicated by the DSMB - &quot;Events&quot;</description>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Outcome</title>
        <description>Modified Rankin Scale (mRS) Score. The mRS is a six point (scored: 0 - 5) scale that measures post stroke disability. A seventh category (mRS = 6) is for patients who have died. A higher score indicates greater degree of disability. Patients scoring '5' are bed ridden, where as those scoring '0' are completely symptom free and independent.</description>
        <time_frame>90-days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Autologous Bone Marrow Mononuclear Cells</title>
            <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Outcome</title>
          <description>Modified Rankin Scale (mRS) Score. The mRS is a six point (scored: 0 - 5) scale that measures post stroke disability. A seventh category (mRS = 6) is for patients who have died. A higher score indicates greater degree of disability. Patients scoring '5' are bed ridden, where as those scoring '0' are completely symptom free and independent.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Autologous Bone Marrow Mononuclear Cells</title>
          <description>Harvest of bone marrow from ischemic stroke patients, isolation and purification of mono-nuclear cell fraction from bone marrow, intravenous administration of autologous bone marrow mono-nuclear cells with a targeted dose of 10 million cells / kg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Numbness</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hospital admission for observation</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture Lumbar Vertebra</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Primary Non Small Cell Lung Carcinoma</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Stroke Expansion</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Carotid Hyperperfusion Syndrome</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Edema</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Leukocytopenia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Prolonged Partial Thromboplastin Time</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Decreased Hemoglobin</sub_title>
                <description>Six Not Study Related. All events grade 1 and 2</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Culture Bottle Skin Contamination, Suspected</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Peripheral Edema</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Nine patients were foley catheter associated. Remaining (one) experienced symptoms prior to infusion</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Increased Alanine Aminotransferase</sub_title>
                <description>All events are grade 1. All patients were on statins. Three patients had transient increase within 30 days and resolved. Three patients continued to fluctuate beyond 30 days. Two patients had normal ALT up till 30 days and later had elevation</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Increased Aspartate Aminotransferase</sub_title>
                <description>All events are grade 1. All patients were on statins. Five patients had transient increase within 30 days and resolved. Two patients continued to fluctuate beyond 30 days. Four patients had normal AST up till 30 days and later had elevation</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Increased INR</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Increased Lipase</sub_title>
                <description>Adjudicated as statin related</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <description>Non-specific Musculoskeletal Pain</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic Transformation of Ischemic Stroke</sub_title>
                <description>All events are grade 1 and were asymptomatic.</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ischemic Stroke</sub_title>
                <description>All events are grade 1, were asymptomatic, and were not study related.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Not Study Related. All occurred greater than 4 months after enrollment</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <description>Not Study Related</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Four events were not study related. Remaining (one) was relative hypotension.</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a Phase I safety and feasibility study, designed without a control group. Small sample size and inclusion of selected patients warrants caution in interpretation of findings. A randomized controlled study is needed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sean I. Savitz, Professor and Director of Stroke</name_or_title>
      <organization>University of Texas Health Science Center</organization>
      <phone>713.500.7083</phone>
      <email>sean.i.savitz@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

